Melanoma-associated antigen B5 (MAGEB5)

**Melanoma-associated antigen B5 (MAGEB5)** is a member of the melanoma antigen gene (MAGE) family, classified as a cancer/testis antigen. MAGEB5 is primarily expressed in testis and various tumors, including melanoma, but not in most healthy somatic tissues. Like other MAGE family members, it contains the conserved MAGE homology domain and localizes to the nucleus, where it is predicted to regulate transcription and participate in the formation of ubiquitin ligase complexes by binding E3 RING domain proteins. MAGEB5 and its family members have a documented role in oncogenesis, supporting cancer cell survival, proliferation, and resistance to apoptosis, in part by modulating key pathways such as p53 signaling and ubiquitin-dependent protein degradation. These features make MAGEB5 a promising tumor-specific antigen for cancer immunotherapy approaches, such as cancer vaccines or T-cell therapies, though it has not yet been specifically targeted by approved drugs. The main therapeutic challenges include ensuring tumor specificity to avoid off-tumor toxicity and addressing the potential for resistance mechanisms common among CT antigens[1][2][3][4].

Other names

MAGEB5CT3.3MAGE-B5Cancer/testis antigen 3.3MAGE family testis and tumor-specific proteinmelanoma antigen family B, 5cancer/testis antigen family 3, member 3

Not directly targeted by current small molecules; as a CT antigen, MAGEB5 is a **potential immunotherapy target**, where cytotoxic T cells or vaccines could recognize MAGEB5-expressing tumor cells. Indirect pathway modulation via association with E3 ligases: influences protein ubiquitination and degradation, potentially affecting cell cycle and apoptosis.